A protective role for estrogens in cardio-vascular disease has long been suspected from the low incidence of vascular events in premenopausal women and the rapid increase in angina, myocardial infarction and stroke following menopause. In an overview of several studies, estrogen treatment in post-menopausal women was found consistently to reduce the risk of myocardial infarction (though not of stroke), with an aggregate risk reduction of 35% (1) . The effect of estrogens can be attributed, in part, to indirect effects on cardio-vascular risk factors, including a reduction in low density lipoprotein-cholesterol, an increase in high density lipoprotein-cholesterol, a decrease in hemostatic factors such as fibrinogen and a decrease in the fibrinolysis inhibitor, plasminogen activator inhibitor-1 (PAI-1) (1-3). However, in recent years much progress has been achieved in identifying direct protective effects of estrogens on the blood vessel wall.
Estrogens, like other steroid hormones, bind with high affinity to their intracellular receptor(s) which then bind to specific DNA sites and alter gene transcription. Functional estrogen receptors have been identified in intact, isolated blood vessels and in cultured human endothelial and smooth muscle cells. However, several biological effects of estrogens cannot be accounted for by regulation of gene expression, since they occur too rapidly to be mediated through the regulation of gene transcription and protein synthesis. The molecular mechanisms of these so-called nongenomic effects remains poorly understood. The regulation of vascular functions by estrogens offers examples of both classical genomic as well as non-genomic effects of these hormones. The actions of estrogens can be (somewhat arbitrarily) divided into (a) effects on vasomotor control and (b) effects on vascular cell proliferation and response to injury (4) .
A number of studies have shown an effect of estrogens on vasomotor tone. Endothelium-dependent vasodilation can be studied by the intracoronary infusion of acetylcholine, which induces the release of the vasodilator nitric oxide (NO). In ovariectomized monkeys, acetylcholine caused a paradoxical vasoconstriction, shown by quantitative coronary angiography. However, estradiol given only 20 min before the test restored a normal vasodilatory response to acetylcholine. Because of its rapidity, the effect of estradiol is most likely non-genomic. Rapid effects have also been demonstrated on smooth muscle cells. For instance, estrogens attenuate voltage-dependent calcium currents which mediate contraction in these cells. Additional classical genomic effects of estrogens on vascular tone include increased expression of genes involved in the production of vasodilators, i.e. prostacyclin synthase and NO synthase (4) .
Smooth muscle cell proliferation, in particular in response to vascular injury is thought to play a major role in the pathogenesis of atherosclerosis. A number of studies have shown that estrogens inhibit proliferation of cultured vascular smooth muscle cells from several sources as well as of ex vivo coronary artery preparations. More definitive evidence was provided by the group of M E Mendelsson (5) who studied the response to injury in a mouse carotid artery model. This model involves the passage of a fine wire down the common carotid artery, causing endothelial denudation. Two weeks later both the injured and contralateral carotid arteries are harvested for assessement of the response to injury. In ovariectomized mice, the injury resulted in reactive increases in vascular intimal and medial thickness, and endothelial and smooth muscle cell proliferation (assessed by bromo-deoxyuridine labeling). Estradiol treatment (started seven days before the injury) resulted in the inhibition of all these parameters. This protective effect was achieved with low nanomolar concentrations of estradiol, compatible with the binding kinetics of the known estrogen receptor ERa. To assess further the involvement of ERa, the same authors have recently reported their study on a mouse model with a targeted disruption of the ERa gene (6) . Although these mice have abnormal reproductive function, they reach a normal weight and display no gross or histological cardio-vascular abnormalities. The response to injury was similar in ovariectomized wild-type and ERa-deficient mice. Treatment with estradiol almost completely inhibited the response to injury both in ERa-deficient and in wild-type mice. These findings clearly indicate that the protective effect of estradiol is not mediated by the classical ERa receptor. This is a surprizing finding since the effects of estrogens on vascular and other cells have so far been assumed to be mediated by ERa. A second estrogen receptor, ERb, has recently been cloned from a rat prostate cDNA library. This isoform is highly homologous to rat ERa, particularly in the DNA-binding domain. Expression of ERb in the aortas from both wildtype and ERa-deficient mice could be demonstrated by reverse transcriptase-PCR. Thus, ERb is an obvious candidate for the protective effects of estradiol in the response to vascular injury.
This study can be expected to lead to much exciting research. Future work should determine whether the ERb receptor is functional in vascular tissue and identify its target genes. It is worth emphasizing that the genes involved in the vascular response to injury are poorly defined. Genes for various growth factors (vascular endothelial growth factor, insulin-like growth factor-I, interleukin-6) and adhesion molecules are estrogenresponsive, but additional genes are likely to be involved. Upregulation of NO production (via induction of NO synthase production and/or non-genomic effects) could not only regulate vasomotor tone, but also modulate the expression of endothelial adhesion molecules and inhibit platelet aggregation. A better definition of the receptor subtypes and the signaling events which mediate the non-genomic effects of estrogens will also be very important. Since ERa and ERb are both nuclear receptors, they are unlikely to mediate these effects. Hence, non-genomic effects are more likely to imply an as yet unidentifed, atypical estrogen receptor. Finally, indirect (i.e. 'extravascular') atheroprotective effects of estrogens need to be considered. Such effects are in no way excluded by the in vivo experiments described above, where the experimental animal as a whole is exposed to estrogens seven days prior to the vascular injury. For instance, estrogens decrease the plasma levels of the fibrinolysis inhibitor PAI-1, probably due to increased hepatic clearance. This effect could upregulate fibrinolysis, thus protecting the vascular wall from the mitogenic effects of fibrin (3). We can look forward to many more surprises in this rapidly evolving field.
